Zoetis Inc. (NYSE:ZTS) Shares Bought by GSB Wealth Management LLC

GSB Wealth Management LLC increased its stake in Zoetis Inc. (NYSE:ZTS) by 33.9% during the third quarter, HoldingsChannel.com reports. The fund owned 8,477 shares of the company’s stock after buying an additional 2,147 shares during the period. GSB Wealth Management LLC’s holdings in Zoetis were worth $1,656,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Quarry LP boosted its holdings in shares of Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after buying an additional 153 shares during the period. LRI Investments LLC acquired a new stake in Zoetis during the 1st quarter valued at $43,000. Fortitude Family Office LLC lifted its holdings in shares of Zoetis by 1,387.5% in the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after purchasing an additional 222 shares in the last quarter. Central Valley Advisors LLC acquired a new position in Zoetis during the second quarter valued at $49,000. Finally, EdgeRock Capital LLC acquired a new stake in Zoetis during the 2nd quarter worth about $56,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Down 0.8 %

Shares of ZTS stock opened at $181.27 on Wednesday. The company has a market capitalization of $82.12 billion, a P/E ratio of 34.93, a P/E/G ratio of 2.79 and a beta of 0.89. The firm has a 50-day moving average price of $189.02 and a 200 day moving average price of $178.25. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The company had revenue of $2.36 billion during the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same period last year, the company posted $1.41 earnings per share. Research analysts forecast that Zoetis Inc. will post 5.83 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be given a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a dividend yield of 0.95%. The ex-dividend date is Thursday, October 31st. Zoetis’s dividend payout ratio is 33.14%.

Wall Street Analyst Weigh In

ZTS has been the subject of a number of research reports. Argus raised Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. increased their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. BTIG Research lifted their price objective on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Stifel Nicolaus raised their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Finally, Piper Sandler upped their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.